Cerebral oedema in enuretic children during low-dose desmopressin treatment: a preventable complication
Language English Country Germany Media print
Document type Case Reports, Journal Article
PubMed
11277376
DOI
10.1007/s004310000686
Knihovny.cz E-resources
- MeSH
- Deamino Arginine Vasopressin adverse effects MeSH
- Child MeSH
- Brain Edema chemically induced prevention & control MeSH
- Enuresis drug therapy MeSH
- Hyponatremia chemically induced prevention & control MeSH
- Water Intoxication chemically induced prevention & control MeSH
- Renal Agents adverse effects MeSH
- Humans MeSH
- Child, Preschool MeSH
- Consumer Product Safety MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Deamino Arginine Vasopressin MeSH
- Renal Agents MeSH
Seven cases of cerebral oedema have been observed in enuretic children during low-dose desmopressin (DDAVP) treatment given in a dose of 7-21 microg daily in the Czech Republic between 1995 and 1999, after the drug started to be marketed for this indication and delivered in simple bottles with a dropper. All seven children (age 5-11 years, four boys) experienced a period of unconsciousness but all recovered without sequelae. In most cases, safety measures were underestimated and natraemia was not regularly controlled. Two children developed cerebral oedema after excessive water intake in preparation for uroflowmetry, another one drank much during a hot summer day, in one diabetes insipidus was not recognised and two children were clearly non-compliant with reduced fluid intake on a long-term basis. Only in one child, no risk factor was found. Conclusion. Proper selection and instruction of patients is needed to avert cerebral oedema during treatment with desmopressin for nocturnal enuresis.
References provided by Crossref.org
